Regeneron's three-monthly gMG drug Livsayis cleared by FDA
Regeneron has joined the crowded gMG market with an siRNA-based therapy, Livsayis, that only needs to be dosed four times a year.
UK modernises gene therapy definition in regulatory revamp
The UK is planning changes to the definition of gene therapies and other genetic medicines, moving to a mechanism-based approach aligned with the EU.
FDA clears Sanofi's Type 3 Gaucher therapy Infilbray
Sanofi's Infilbray has become the first drug to treat neurological symptoms of rare lysosomal storage disorder Type 3 Gaucher disease (GD3) in the US.
Mixed results for experimental Alzheimer's therapies at CTAD
The CTAD Alzheimer's meeting hears encouraging data for new drug candidates from the likes of Biogen, AriBio, and BMS - but also some disappointments.
MSD stops trials of BTK inhibitor for blood cancers
MSD has stopped development of BTK inhibitor nemtabrutinib, acquired via its $2.7bn takeover of ArQule, after trial results pointed to a safety issue.
Partner Content
The PM Awards aren’t just for agencies. They’re for the peop...
For decades, the PM Awards have been a fixture in the pharma and healthcare communications calendar
PMi Awards 2026: innovation, connection and a changing indus...
One of the things I enjoyed most about this year’s PM Society PMi Awards was the sheer breadth of the community in the room.
LEAP HR: Life Sciences Europe
Europe’s Only Industry-Specific Meeting Advancing HR Excellence in Life Sciences
Rational Based Drug Design Summit Europe
Driving Safer, Faster & More Efficient Discovery Across Europe
Evolution Summit 2027 to Convene Senior Clinical Development...
Westlake Village, CA: Marcus Evans today announced the Evolution Summit 2027, an invitation-only gathering of senior clinical trial executives
